Last reviewed · How we verify
Supportive treatment
Supportive treatment, marketed by Hoffmann-La Roche, holds a significant position in its therapeutic segment. The key composition patent, set to expire in 2028, provides a strong competitive advantage by protecting the drug's market exclusivity. The primary risk lies in potential competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Supportive treatment |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Acceptability of Artificial Intelligence in the Diagnosis of Prostate Cancer (NA)
- WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER (NA)
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
- Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors (NA)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Effect of Kinesio Taping Application in Addition to Pilates Exercises on Core Muscle Thickness, Cognition and Mental Fatigue in Individuals With Non-specific Low Back Pain (NA)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense Strong (NA)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Supportive treatment CI brief — competitive landscape report
- Supportive treatment updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI